Neurosurgeon Named Chief Clinical Strategy Officer at inTRAvent Medical

inTRAvent Medical has appointed Adam S. Arthur, M.D., as chief Clinical Strategy Officer (CCSO). He is tasked with leading the company’s clinical strategy for the upcoming launch of SOLOPASS—inTRAvent’s platform for external ventricular drain (EVD) placement—and guiding the development of additional minimally invasive applications.

Dr. Arthur brings to his new role a wealth of experience from his career in both open cerebrovascular and endovascular neurosurgery. As the James T. Robertson Endowed Professor and Chair of Neurosurgery at the University of Tennessee Health Science Center, and a practicing neurosurgeon at Semmes Murphey Clinic, he has been at the forefront of neurovascular treatment advancements. Dr. Arthur’s leadership in clinical trials, including the pivotal WEB-IT, STEM, and MIND studies, underscores his commitment to advancing innovation to improve patient outcomes.

“Dr. Arthur’s expertise and forward-thinking approach to neurosurgery make him an invaluable addition to our team,” inTRAvent Medical CEO Adam Barner stated. “His insights will help guide the continued clinical development of our SOLOPASS platform to address significant unmet clinical needs.”

inTRAvent’s U.S. Food and Drug Administration-cleared SOLOPASS delivers real-time ultrasound imaging during EVD placement procedures, integrating frameless fixation with a rigid guidance system designed to support precise localization and navigation in critical-care environments. The system, designed from inception for the critical-care setting, combines 2D and 3D ultrasound imaging, artificial intelligence, and trajectory guidance to provide real-time intra-procedural localization and navigation. The solution avoids the limitations of traditional systems, which rely on preoperative images that can become unreliable and no longer reflect actual anatomy due to brain shift or evolving pathology.

“Bringing advanced neuronavigation featuring real-time imaging to the bedside has the potential to change the standard of care for EVD placement,” Arthur said. “Importantly, this platform also creates a pathway for minimally invasive approaches to treating intracranial hemorrhage—without the need to move critically ill patients from the ICU.”

inTRAvent Medical Partners is a medical device company dedicated to bringing intra-operative imaging and navigation to the bedside to improve the safety and efficacy of neurosurgical procedures. Its first product, SOLOPASS enables simple, portable neuro-navigation using 2D and 3D ultrasound imaging, AI, and trajectory guidance for intra-procedural localization and navigation.